多聚二磷酸腺苷酸核糖聚合酶抑制剂抗肿瘤研究进展  

Advances in the antitumor research of PARP inhibitor

作　　者：李绪渊[1] 李蔚冰[1] 林英城[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院内科,515031

出　　处：《国际肿瘤学杂志》2011年第3期185-188,共4页Journal of International Oncology

摘　　要：多聚二磷酸腺苷酸核糖聚合酶（PARP）在DNA修复中具有重要作用。在DNA同源修复障碍的肿瘤细胞中抑制PARP活性，可以引起基因组的不稳定乃至细胞死亡。基础研究证实PARP抑制剂能增强肿瘤细胞对化放疗的敏感性。在早期临床研究中，无论单一用药或联合化疗药物，PARP抑制剂都显示了在抗肿瘤治疗领域的潜力。Poly ADP-Ribose Polymerase （PARP） plays an important role in the detection and repair of DNA damage. Inhibition of the PARP activity in the homologous-recombination defective cancer cell could lead to genomic instability and uhimately cause cell death. In preclinical study PARP inhibitors have demonstrated the capacity of enhancing sensitivity of cancel cells to chemotherapy agents and radiation. PARP inhibitors also showed antitumour potential in early clinical trials as monotherapy or combined with chemotherapy.

关 键 词：聚ADP核糖聚合酶类 肿瘤 酶抑制剂 合成致死 

分 类 号：R96[医药卫生—药理学]